Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
HLS Therapeutics Inc (TSE:HLS)
TSX:HLS
HLS Therapeutics Inc (HLS) Stock Price & Analysis
41 Followers
HLS Stock Chart & Stats
Day’s RangeC$0 - C$0
52-Week RangeC$3.15 - C$7.12
Previous CloseC$3.54
Volume4.60K
Average Volume (3M)5.68K
Market Cap
C$112.62M
Enterprise ValueC$91.91M
Total Cash (Recent Filing)$21.95M
Total Debt (Recent Filing)$6.88M
Price to Earnings (P/E)―
Beta0.60
Next Earnings
Aug 08, 2024EPS Estimate
-C$0.21Last Dividend Ex-Date
Apr 27, 2023Dividend YieldN/A
Share Statistics
EPS (TTM)-1.17
Shares Outstanding31,814,547
10 Day Avg. Volume8,756
30 Day Avg. Volume5,681
Standard Deviation0.14
R-Squared0.12
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)-1.25
Price to Sales (P/S)1.73
Price to Cash Flow (P/CF)5.40
P/FCF Ratio3.20
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.46
Enterprise Value/Gross Profit1.66
Enterprise Value/Ebitda7.13
Forecast
1Y Price Target
C$5.31Price Target Upside45.48% Upside
Rating ConsensusHold
Number of Analyst Covering4
HLS Therapeutics Inc News
PremiumCompany Announcements
HLS Therapeutics Divests Royalty Interest, Updates GuidancePremiumCompany Announcements
HLS Therapeutics Shareholders Back Board and Auditors
PremiumCompany Announcements
HLS Therapeutics Boosts Treatment Adherence with Support Programs
PremiumCompany Announcements
HLS Therapeutics Faces Q1 Challenges, Ends Pfizer DealPremiumCompany Announcements
HLS Therapeutics Announces Q1 2024 Financial Results
PremiumCompany Announcements
HLS Therapeutics Showcases at Investor Conference
PremiumCompany Announcements
HLS’s VASCEPA Shows Promise for Heart Disease Patients
PremiumCompany Announcements
HLS Therapeutics Reports Growth and Optimism for 2024Options Prices
Currently, No data available
---
Ownership Overview
61.68% Insiders
0.01% Mutual Funds
1.61% Other Institutional Investors
36.70% Public Companies and
Individual Investors
HLS FAQ
What was HLS Therapeutics Inc’s price range in the past 12 months?
HLS Therapeutics Inc lowest stock price was C$3.15 and its highest was C$7.12 in the past 12 months.
What is HLS Therapeutics Inc’s market cap?
Currently, no data Available
When is HLS Therapeutics Inc’s upcoming earnings report date?
HLS Therapeutics Inc’s upcoming earnings report date is Aug 08, 2024 which is in 35 days.
How were HLS Therapeutics Inc’s earnings last quarter?
HLS Therapeutics Inc released its earnings results on May 09, 2024. The company reported -C$0.261 earnings per share for the quarter, missing the consensus estimate of -C$0.218 by -C$0.043.
Is HLS Therapeutics Inc overvalued?
According to Wall Street analysts HLS Therapeutics Inc’s price is currently Undervalued.
Does HLS Therapeutics Inc pay dividends?
HLS Therapeutics Inc pays a Quarterly dividend of C$0.05 which represents an annual dividend yield of N/A. See more information on HLS Therapeutics Inc dividends here
What is HLS Therapeutics Inc’s EPS estimate?
HLS Therapeutics Inc’s EPS estimate is -C$0.21.
How many shares outstanding does HLS Therapeutics Inc have?
HLS Therapeutics Inc has 31,814,547 shares outstanding.
What happened to HLS Therapeutics Inc’s price movement after its last earnings report?
HLS Therapeutics Inc reported an EPS of -C$0.261 in its last earnings report, missing expectations of -C$0.218. Following the earnings report the stock price went down -13.18%.
Which hedge fund is a major shareholder of HLS Therapeutics Inc?
Currently, no hedge funds are holding shares in TSE:HLS
---
HLS Therapeutics Inc Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
C$5.31 (45.48% Upside)
C$5.31 (45.48% Upside)
Insider Transactions
Bought Shares
Worth C$9.9K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-38.54%
12-Months-Change
Fundamentals
Return on Equity
-26.66%
Trailing 12-Months
Asset Growth
-15.55%
Trailing 12-Months
Company Description
HLS Therapeutics Inc
HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties. The company products include Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia and Perseris. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue. The company operates in Canada and the United States.
---
HLS Stock 12 Month Forecast
Average Price Target
C$5.31
▲(45.48% Upside)
Technical Analysis
Best Analysts Covering HLS
1 Year
1 Year Success Rate
9/29 ratings generated profit
1 Year Average Return
+6.60%
reiterated a buy rating yesterday
Copying David Martin PhD's trades and holding each position for 1 Year would result in 31.03% of your transactions generating a profit, with an average return of +6.60% per trade.
---